Table 5.
Progression of cardiomyopathy, determined as annualized rate of change in LVMI, in male and female patients stratified by the presence or absence of LVH at baseline.
| FOS Evaluable Treated Cardiac cohort |
Kampmann et al. (untreated) [8] |
|||
|---|---|---|---|---|
| Mean annualized LVMI slope (SEM) [95% CI],a g/m2.7/y | ||||
| Baseline LVH status | n | n | ||
| Males | ||||
| Total | 71 | 0.33 (0.10) [0.13, 0.53] |
39 | 4.07 (1.03) |
| LVH | 29 | 0.19 (0.16) [− 0.13, 0.50] |
18 | 6.59 (8.5) |
| No LVH | 42 | 0.47 (0.13) [0.22, 0.72] |
Not availableb | |
| Females | ||||
| Total | 93 | 0.48 (0.09) [0.30, 0.66] |
39 | 2.31 (0.81) |
| LVH | 45 | 0.77 (0.14) [0.49, 1.05] |
15 | 3.77 (7.7) |
| No LVH | 48 | 0.19 (0.11) [− 0.03, 0.41] |
Not availableb | |
CI, confidence interval; FOS, Fabry Outcome Survey; LVH, left ventricular hypertrophy; LVMI, left ventricular mass indexed to height; SEM, standard error of the mean.
a
Median (range) follow-up period: FOS, 5.2 (1.5 to 11.4) years; Kampmann et al., 4.5 (1.1 to 9.0) years [8].
b
95% CI for LVMI data were not published by Schiffmann et al. [21].